Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial

被引：0
|
作者：
Strauss, A. [1 ]
Heinrich, D. [2 ]
Parker, C. [3 ,4 ]
Shan, M. [5 ]
Wilhelm, S. [5 ]
Garcia-Vargas, J. [5 ]
O'Bryan-Tear, C. G. [6 ]
Sartor, O. [7 ]
机构：
[1] Univ Med Gottingen, Urol Klin, Gottingen, Germany
[2] Akershus Univ Hosp, Lorenskog, Norway
[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[4] Inst Canc Res, Sutton, Surrey, England
[5] Bayer Healthcare, Whippany, NJ USA
[6] Algeta ASA, Oslo, Norway
[7] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V553
引用
收藏
页码：177 / 178
页数：2
相关论文
共 50 条
  • [31] 3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
    Parker, Chris
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Coleman, Robert E.
    Skjorestad, Irene
    Fang, Fang
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial
    Vogelzang, Nicholas J.
    Helle, Svein Inge
    Johannessen, Dag Clement
    O'Sullivan, Joe M.
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel (D) therapy in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S., I
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Shan, M.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [34] Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA)
    Vogelzang, Nicholas J.
    Parker, Chris
    Nilsson, Sten
    Coleman, Robert Edward
    O'Bryan-Tear, C. Gillies
    Shan, Minghua
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [35] Time to first skeletal-related event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis
    Coleman, R.
    Fossa, S.
    Chodacki, A.
    Wedel, S.
    Bruland, O.
    Staudacher, K.
    Garcia-Vargas, J.
    Sartor, O.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S688 - S688
  • [36] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
    Vogelzang, Nicholas J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
  • [37] Long-term safety and real world clinical experience of radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the phase 3 ALSYMPCA study
    Franzen, L.
    Sartor, O.
    Parker, C.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S271 - S271
  • [38] Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223
    Parker, C.
    O'Bryan-Tear, C. G.
    Bolstad, B.
    Lokna, A.
    Nilsson, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [39] 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study
    Nilsson, Sten
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Bottomley, David
    Coleman, Robert E.
    Skjorestad, Irene
    Wahba, Mona
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [40] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345